Spruce Biosciences (SPRB) to Release Quarterly Earnings on Wednesday

Spruce Biosciences (NASDAQ:SPRB) is expected to be releasing its earnings data on Wednesday, March 12th. Analysts expect Spruce Biosciences to post earnings of ($0.28) per share for the quarter.

Spruce Biosciences Stock Performance

Shares of NASDAQ SPRB opened at $0.36 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.36 and a quick ratio of 5.36. Spruce Biosciences has a 1 year low of $0.34 and a 1 year high of $5.95. The firm has a fifty day moving average price of $0.39 and a 200-day moving average price of $0.45. The stock has a market cap of $14.76 million, a PE ratio of -0.38 and a beta of 2.37.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SPRB. HC Wainwright reissued a “neutral” rating on shares of Spruce Biosciences in a report on Monday, December 16th. Oppenheimer restated a “market perform” rating on shares of Spruce Biosciences in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market perform” rating and set a $3.00 target price on shares of Spruce Biosciences in a research report on Wednesday, December 11th. Guggenheim restated a “neutral” rating on shares of Spruce Biosciences in a report on Thursday, December 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $1.50 price target (down from $2.00) on shares of Spruce Biosciences in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $2.38.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.